# A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age < 12 years) with severe hemophilia A.

Published: 22-04-2013
Last updated: 24-04-2024

Main objectives: safety and efficacy of BAY94-9027 for prophylaxis and treatment of bleeding in PTP with hemophilia ASecondary objective: PK

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Recruitment stopped |
| **Health condition type** | Coagulopathies and bleeding diatheses (excl thrombocytopenic) |
| **Study type** | Interventional |

## Summary

### ID

NL-OMON45210

**Source**
ToetsingOnline

**Brief title**
PROTECT KIDS

### Condition

- Coagulopathies and bleeding diatheses (excl thrombocytopenic)

**Synonym**
Hemophilia A

**Research involving**
Human

## Sponsors and support

**Primary sponsor:** Bayer
**Source(s) of monetary or material Support:** Bayer B.V.

## Intervention

**Keyword:** factor VIII, hemophilia A, pediatric study, profylaxis

## Outcome measures

### Primary outcome

Number of bleeding events during prophylactic treatment

Assessment of PK, including Cmax, incremental recovery, Mean Residence Time (MRT), Apparent volume of distribution at steady state (Vss), half-life, area under the curve (AUC), and clearance, in at least 12 subjects in each age subgroup, with at least 4 pre-selected time points between pre-dose and 72 h post-infusion.

Response of acute bleeding events to treatment will be rated using a 4-point scale (poor, moderate, good, or excellent) by the subject/parent or by the treating physician if the subject is hospitalized.

### Secondary outcome

Inhibitor development after 10-15 and 50 ED

Assess incremental recovery in all subjects

Safety and tolerability assessments

# Study description

### Background summary

The primary goal of the BAY94-9027 program is to develop a longer acting recombinant FVIII (rFVIII) for use in prophylaxis across different dosing regimens. It is expected that improved adherence to prophylaxis and consequently better long-term outcomes could be achieved if treatment were more convenient, and the duration of effect prolonged. A longer half-life of FVIII would result in a reduction in the number of infusions required each week to maintain FVIII trough levels above 1 IU/dl, fewer infusions to provide hemostasis during surgical procedures, and would provide subjects with a greater number of potential choices for tailoring treatment to their own specific bleeding patterns. It is expected that a longer acting rFVIII will be of benefit following dental, surgical, and other invasive challenges by reducing a need for frequently repeated treatment in order to maintain adequate hemostasis.

### Study objective

Main objectives: safety and efficacy of BAY94-9027 for prophylaxis and treatment of bleeding in PTP with hemophilia A

Secondary objective: PK

### Study design

The study consists of at least 6 months of prophylactic treatment (or the amount of time required for a subject to accumulate a minimum of 50 exposure days) with BAY 94-9027 in previously treated severe hemophilia A patients.

All subjects will receive intravenous prophylactic administration of BAY 94-9027 at least once every 7-days. Doses and dose intervals (2 times weekly, every 5 days, or every 7 days) will be determined by the subject*s clinical need, level of activity, and known past bleeding history and may be adjusted as needed.

BAY 94-9027 will also be used for treatment of any breakthrough bleeding events.

After the Screening (Visit 1) and Baseline (Visit 2) visits, all subjects will be evaluated for inhibitor development monthly for the first 3 months of treatment, and again after 6 months or 50 exposure days.

Pharmacokinetics will be performed in at least 12 subjects in each age subgroup (age groups 6 to < 12 years and < 6 years). Blood samples for pharmacokinetic

analyses will be collected once at pre-selected time points between pre-dose and 72 hours post-infusion. Attempt will be made to collect PK at the baseline visit, but if blood draw volumes or the convenience to the subject/parent will not permit, PK may be obtained at any scheduled visit during the main study.

Infusions and bleeding events will be documented in an electronic patient diary throughout the study.

All subjects completing the main study will be offered participation in an optional extension study for collection of observations for at least 50 additional exposure days. Subjects will continue to be monitored for inhibitor development every 6 months and at the end of the study.

**Intervention**

Subjects will receive BAY 94-9027 once or a number of times per week (see section *study design*).

**Study burden and risks**

Up to 10 visits, 2 times physical examination, at 3 time points in the study 2 QoL, ongoing electronic patient diary documentation, 13 blood samples

Benefit: potential to provide prophylactic protection from bleeding with a reduced number of injections

Risk: development of inhibitory antibodies against FVIII or BAY94-9027

# Contacts

**Public**
Bayer

Energieweg 1
Mijdrecht 3641 RT
NL
**Scientific**
Bayer

Energieweg 1
Mijdrecht 3641 RT
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Children (2-11 years)

## Inclusion criteria

- Males < 12 years of age
- Subjects with severe hemophilia A
- Previously treated with FVIII for > 50 exposure days
- Subjects in the expansion group < 6 years of age

## Exclusion criteria

- Subjects with current evidence of or history of inhibitors to FVIII
- Any other inherited or acquired bleeding disorder
- Platelet counts < 100,000/mm^3
- Creatinine > 2x the upper limit of normal
- Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) > 5x the upper limit of normal

# Study design

## Design

| | |
|---|---|
| Study phase: | 3 |
| Study type: | Interventional |
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Prevention |

## Recruitment

NL

| | |
|---|---|
| Recruitment status: | Recruitment stopped |
| Start date (anticipated): | 27-09-2013 |
| Enrollment: | 5 |
| Type: | Actual |

## Medical products/devices used

| | |
|---|---|
| Product type: | Medicine |
| Brand name: | BAY 94-9027 (niet beschikbaar) |
| Generic name: | n.v.t. |

# Ethics review

| | |
|---|---|
| Approved WMO Date: | 22-04-2013 |
| Application type: | First submission |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 23-08-2013 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 27-08-2013 |
| Application type: | First submission |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 17-10-2013 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 18-12-2013 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO | |

| | |
|---|---|
| Date: | 12-02-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 30-04-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 08-05-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 18-08-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 27-08-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 01-10-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 09-10-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 24-10-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 24-11-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO | |

| | |
|---|---|
| Date: | 05-12-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 23-12-2014 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 02-10-2015 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 22-12-2015 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 12-08-2016 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 21-09-2016 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 10-10-2016 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 12-10-2016 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 28-12-2016 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO | |

| | |
|---|---|
| Date: | 19-01-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 05-04-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 11-05-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 09-08-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 14-09-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 18-10-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 19-10-2017 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 17-10-2018 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 19-10-2018 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO | |

| | |
|---|---|
| Date: | 07-01-2019 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |
| Approved WMO Date: | 11-01-2019 |
| Application type: | Amendment |
| Review commission: | METC Universitair Medisch Centrum Utrecht (Utrecht) |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID |
|---|---|
| EudraCT | EUCTR2012-004434-42-NL |
| ClinicalTrials.gov | NCT01775618 |
| CCMO | NL43199.041.13 |